CYTODYN INC. DL -,01 WKN: A0YHA5 ISIN: US23283M1018 Kürzel: 296 Forum: Aktien Thema: Hauptdiskussion

CytoDyn Anticipates Revenue Commencing in August 2019 from Use of PA-14 and/or PRO 140 in Diagnostic Test GlobeNewswireJuly 1, 2019, 12:00 PM GMT+2 CytoDyn Signs Non-binding Agreement for Diagnostic License and Supply Agreement with IncellDX for PA-14 and/or  PRO 140 (non-commercial grade) Collaboration represents an immediate revenue opportunity as a diagnostic test for receptor occupancy and the existence of CCR5 on cancer tissue and in HIV “Our non-binding agreement with IncellDX, subject to execution of a definitive agreement, which is expected to be finalized in July 2019, may lead to our first ever product revenues,” stated CytoDyn President and CEO, Nader Pourhassan, Ph.D.  “Importantly, the PRO 140 used for the PA-14 diagnostic test is non-commercial grade product in storage.  As such, this transaction allows CytoDyn to potentially realize significant value from product that would have very likely been discarded,” continued Dr. Pourhassan.  “Each diagnostic test may use 20 micro mg (mcg) of PRO 140 (1 mg = 1,000 mcg), implying significant revenue opportunity for CytoDyn, since any use of leronlimab for commercial purposes will require this diagnostic test.  Bottom ***, this is a small first step in realizing full value from PRO 140,” concluded Dr. Pourhassan. https://finance.yahoo.com/news/cytodyn-anticipates-revenue-commencing-august-100000970.html?.tsrc=rss

👋👋👋